JO
LXEO icon

John Overdeck’s Lexeo Therapeutics LXEO Stock Holding History

John Overdeck’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-181,676
Closed -$1.04M – 5282
2026
Q1 		$1.04M Sell
181,676
-218,891
-55% -$1.55M ﹤0.01% 3243
2025
Q4 		$3.98M Buy
400,567
+315,804
+373% +$2.88M 0.01% 1913
2025
Q3 		$563K Buy
84,763
+15,521
+22% +$75.1K ﹤0.01% 2928
2025
Q2 		$278K Buy
69,242
+32,618
+89% +$107K ﹤0.01% 2816
2025
Q1 		$127K Buy
+36,624
New +$162K ﹤0.01% 2932

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

John Overdeck's LXEO Position: Q2 2026 in Review

John Overdeck sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 181,676 shares — an estimated $1.04M sold.

John Overdeck first reported a position in LXEO in Q1 2025 and held it in 5 quarters. The position peaked at $3.98M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • John Overdeck reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 181,676 Lexeo Therapeutics shares in Q2 2026, an estimated $1.04M.
  • John Overdeck first reported a position in Lexeo Therapeutics in Q1 2025 and held it in 5 quarters.
  • John Overdeck's Lexeo Therapeutics position peaked at $3.98M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.